New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on February 21, 2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Lilly Endowment Inc, a significant shareholder, has sold 9,985 shares of Eli Lilly & Co stock, totaling a transaction value of $8,771,255. This move is noteworthy given the substantial amount involved.
Recent Updates on LLY stock
Eli Lilly & Co. has recently experienced significant developments impacting its stock. The company raised its price target following strong Q4 results and the announcement of FY25 EPS guidance, aligning with consensus expectations for future revenue and earnings growth. Additionally, Eli Lilly’s next-generation obesity drug trials have shown unexpectedly rapid weight loss in participants, prompting dose adjustments. The firm also filed an automatic mixed securities shelf and announced a licensing agreement with OliX Pharmaceuticals for a Phase 1 candidate targeting metabolic disorders. Moreover, the VIVID-2 study results for its Crohn’s disease treatment, Omvoh, demonstrated long-term efficacy and safety, contributing to a positive outlook for its innovative pipeline and market-leading treatments.
More about Eli Lilly & Co
YTD Price Performance: 12.51%
Average Trading Volume: 3,621,227
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $813.8B